Skip to main content

Table 2 CYP2C19, CYP2D6, CYP3A5, AND SULT1A1 genotype frequencies

From: Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer

Genotype

Predicted phenotypes

(n)

% of total

Age (median)

Genotypes

(n)

Genotype frequency

CYP2C191

*2/*2

(4)

4.4

63

*2/*2

(4)

0.03

 

*1/*2

(15)

16.7

66

*1/*2

(15)

0.21

 

*1/*1

(35)

38.9

62

*1/*1

(35)

0.35

 

*1/*17 and *2/*17

(33)

36.7

62

*1/*17

(24)

0.27

     

*2/*17

(9)

0.08

 

*17/*17

(3)

3.3

65

*17/*17

(3)

0.05

CYP2D62

PM

(6)

6.7

65

*4/*4

(4)

0.04

     

*4/*5

(2)

0.01

 

IM

(32)

35.5

55

*1/*3

(1)

0.01

     

*1/*4

(27)

0.29

     

*1/*5

(3)

0.04

     

*1/*6

(1)

0.01

 

Wt/Wt

(51)

56.7

60

*1/*1

(51)

0.48

 

UM

(1)

1.1

50

*1/*2 ×2

(1)

 

CYP3A5

Vt/Vt

(76)

84.4

60

*3/*3

(76)

0.85

 

Wt/Vt

(14)

15.6

73

*1/*3

(14)

0.50

 

Wt/Wt

(0)

  

*1/*1

(0)

 

SULT1A1

Vt/Vt

(14)

15.6

61

*2/*2

(14)

0.11

 

Wt/Vt

(32)

35.5

59

*1/*2

(32)

0.44

 

Wt/Wt

(44)

48.9

59

*1/*1

(44)

0.45

SULT1A1 copy numbers

1

(3)

3.3

59

   
 

2

(59)

65.6

60

   
 

3

(21)

23.3

67

   
 

4

(5)

5.6

72

   
 

5

(2)

2.2

69

   
  1. 1*2/*2, subjects homozygous for the variant allele CYP2C19*2; *1/*2, subjects heterozygous for the variant allele CYP2C19*2; intermediate metabolizer, subjects homozygous for the wild type allele CYP2C19*1 and with CYP2C19*2/*17; *1/*17 subjects heterozygous for the CYP2C19*17 variant allele; *17/*17 Vt*17 subjects homozygous for the CYP2C19*17 variant allele
  2. 2PM, poor metabolizer CYP2D6; IM, intermediate metabolizer wild type/variant type CYP2D6; Wt/Wt, wild type/wild type CYP2D6; UM, ultra rapid metabolizer CYP2D6.